Product category:
Laboratory and scientific manufacturing services
News Release from: Capsugel
Edited by the Laboratorytalk Editorial
Team on 17 December 2003
Powder micro-dosing agreement extended
Meridica has announced the renewal of its showcasing agreement for Xcelodose, its powder micro-dosing technology, with pharmaceutical services organisation Quintiles
Meridica has announced the renewal of its showcasing agreement for Xcelodose, its powder micro-dosing technology, with pharmaceutical services organisation Quintiles The showcasing agreement, which has already been in place for over a year, makes an Xcelodose system available to Quintiles's customers in Quintiles's GMP facilities at Edinburgh, UK, as well as providing the framework for co-promotion of the Xcelodose technology to the pharmaceutical industry
This article was originally published on Laboratorytalk on 25 Jun 2003 at 8.00am (UK)
Related stories
A dose of success
Precision automated powder filling technology for use in early stage clinical trials has been licensed to five out of the top ten global pharmaceutical companies
Micro-filling system has 50% increased throughput
Capsugel will unveil successor to Xcelodose system for micro-dosing drug powders into capsules and vials at the American Association of Pharmaceutical Scientists (AAPS) meeting in San Diego this month
Quintiles currently features Xcelodose as a unique technology, which has enabled the company to offer its customers micro-dosing of pharmaceutical drug powder for use in oral dose and inhaled dose clinical supplies.
The Xcelodose technology has a number of substantial business benefits, including potentially shortening the drug development process, by reducing the need for costly stability studies, and the avoidance of laborious hand-filling of capsules.
Phil Woodhead, Quintiles's VP pharmaceutical sciences Europe, said: "The successful showcasing agreement with Meridica has enabled us to offer the innovative Xcelodose technology to the marketplace.
"This has clearly fulfilled an unmet market need as, since its installation in May 2002, it has been in constant demand by pharmaceutical companies.
"We are pleased to extend this agreement with Meridica and our investment in the Xcelodose system serves to reinforce Quintiles's commitment to providing innovative technologies to its clients".
David Edwards, Meridica's director of strategic marketing, said: "As the world's largest pharmaceutical services organisation, Quintiles provides a major endorsement of the value of our Xcelodose technology to the pharmaceutical industry.
"We are delighted to continue our relationship, which we believe has been mutually beneficial.
"We believe the relationship has worked extremely well at all levels between Meridica and Quintiles and look forward to continuing success in developing this market.".
• Capsugel: contact details and other news
• Email this article to a colleague
• Register for the free Laboratorytalk email newsletter
• Laboratorytalk Home Page
Search the Pro-Talk network of sites
